4M Therapeutics Inc. Announces New Patent License Agreement

FOR IMMEDIATE RELEASE: Thursday, June 30, 2022

Alexandra-Sophia C. Piliotis

4M Therapeutics Inc.

brenda@4mtx.net

4M Therapeutics Inc. Announces New Patent License Agreement

[Skillman, NJ]: 4M Therapeutics Inc. (4MTx) today announced that it has signed an exclusive patent license agreement with Massachusetts Institute of Technology (MIT) for technology relating to treatment of bipolar disorder and other brain disorders.

“We are very excited to sign this license with MIT, which enable us to advance 4MT-02, an important part of the 4MTx pipeline,” says Pablo Lapuerta, Founder and Chief Executive Officer at 4MTx. “This agreement brings forth a great opportunity for 4MT-02, an advanced compound that could be ready for clinical trials in 2024.”

“I am very happy to see 4MT-02 move forward in pre-clinical development,” said Dr. Lawrence Goldstein, Director at 4MTx. “4MT-02 was developed as a potential therapeutic agent owing to great scientific progress in understanding how 4MT-02 targets key pathways in the brain.”

This patent license agreement is one of several steps that 4MTx has taken to build and strengthen its intellectual property. The terms of this agreement remain confidential as agreed between the parties.

About 4MTx:  

4M Therapeutics Inc. is a startup biotech company based on the principle that the study of human brain cells represents an important advance in neuroscience discovery. 4MTx has developed a pipeline of small molecules by studying their effects on brain cells derived from human induced pluripotent stem cells. The initial focus is bipolar disorder and Alzheimer's disease, conditions where targeted drug discovery can support and improve neuroplasticity and neurogenesis. The scientific founders are world-leaders in neurobiology, chemistry, and the pharmacology of neuroplasticity. For more information, please visit www.4mtx.net and engage with us on LinkedIn.